User login
For the first time, the task force recommended screening for anxiety in children aged 8-18 years who do not have a diagnosed anxiety disorder and are not showing signs or symptoms of anxiety.
This “B” recommendation reflects “moderate certainty” evidence that screening for anxiety in 8- to 18-year-olds has a moderate net benefit, the task force said.
However, the task force found “insufficient” evidence to weigh the balance of benefits and harms of screening for anxiety in children aged 7 and younger and therefore issued an “I” statement.
The task force also recommended screening for children aged 12-18 years for major depressive disorder (“B” recommendation) but said there is insufficient evidence to weigh the balance of benefits and harms of screening for depression in children aged 11 and younger (“I” statement).
These recommendations are in line with the 2016 recommendations on depression screening from the USPSTF.
“Fortunately, screening older children for anxiety and depression can identify these conditions so children and teens can receive the care that they need,” task force member Martha Kubik, PhD, RN, with George Mason University, Fairfax, Va., said in a statement.
“Unfortunately, there are key evidence gaps related to screening for anxiety and depression in younger children and screening for suicide risk in all youth,” added task force member Lori Pbert, PhD, University of Massachusetts, Worcester.
“We are calling for more research in these critical areas so we can provide health care professionals with evidence-based ways to keep their young patients healthy,” Dr. Pbert said.
Suicide screening
Turning to suicide, the task force says there is not enough evidence to recommend for or against screening for suicide risk in children and adolescents, and therefore issued an “I” statement – in line with the 2014 recommendation statement from the task force.
The task force acknowledged that the American Academy of Pediatrics, the American Foundation for Suicide Prevention, and experts from the National Institute of Mental Health have released a “Blueprint for Youth Suicide Prevention” that recommends universal screening for suicide risk in youth 12 years or older, while children aged 8-11 years should be screened as clinically indicated.
The task force’s final recommendation statements and corresponding evidence summaries on screening children and adolescents for anxiety, depression and suicide were published online Oct. 11, 2022, in JAMA and the USPSTF website.
The final recommendations are consistent with the 2022 draft recommendation statements on these topics.
The task force emphasized that screening is only the first step in helping children and adolescents with anxiety and depression. Youth who screen positive need further evaluation to determine if they have anxiety or depression.
After diagnosis, youth should participate in shared decision-making with their parents and healthcare professional to identify the best treatment or combination of treatments.
Only a first step
In an accompanying editorial, John Walkup, MD, with Ann and Robert H. Lurie Children’s Hospital, Chicago, and coauthors made the point that, for the potential of screening for pediatric anxiety disorders to be fully realized, research focused on the process of screening from evaluation to treatment needs to be a priority.
“Perhaps most critical is developing a smart and sophisticated process of screening aligned with evidence-based treatment strategies that brings added value to routine pediatric medical care and that improves physical and mental health outcomes for children and adolescents,” they wrote.
Members of the USPSTF disclosed no relevant financial relationships. Dr. Walkup reported serving as an unpaid member of the scientific council of the Anxiety and Depression Association of America, receiving royalties for anxiety-related continuing medical education activities from Wolters Kluwer and honoraria for anxiety presentations from the American Academy of Child and Adolescent Psychiatry and the American Academy of Pediatrics.
A version of this article first appeared on Medscape.com.
For the first time, the task force recommended screening for anxiety in children aged 8-18 years who do not have a diagnosed anxiety disorder and are not showing signs or symptoms of anxiety.
This “B” recommendation reflects “moderate certainty” evidence that screening for anxiety in 8- to 18-year-olds has a moderate net benefit, the task force said.
However, the task force found “insufficient” evidence to weigh the balance of benefits and harms of screening for anxiety in children aged 7 and younger and therefore issued an “I” statement.
The task force also recommended screening for children aged 12-18 years for major depressive disorder (“B” recommendation) but said there is insufficient evidence to weigh the balance of benefits and harms of screening for depression in children aged 11 and younger (“I” statement).
These recommendations are in line with the 2016 recommendations on depression screening from the USPSTF.
“Fortunately, screening older children for anxiety and depression can identify these conditions so children and teens can receive the care that they need,” task force member Martha Kubik, PhD, RN, with George Mason University, Fairfax, Va., said in a statement.
“Unfortunately, there are key evidence gaps related to screening for anxiety and depression in younger children and screening for suicide risk in all youth,” added task force member Lori Pbert, PhD, University of Massachusetts, Worcester.
“We are calling for more research in these critical areas so we can provide health care professionals with evidence-based ways to keep their young patients healthy,” Dr. Pbert said.
Suicide screening
Turning to suicide, the task force says there is not enough evidence to recommend for or against screening for suicide risk in children and adolescents, and therefore issued an “I” statement – in line with the 2014 recommendation statement from the task force.
The task force acknowledged that the American Academy of Pediatrics, the American Foundation for Suicide Prevention, and experts from the National Institute of Mental Health have released a “Blueprint for Youth Suicide Prevention” that recommends universal screening for suicide risk in youth 12 years or older, while children aged 8-11 years should be screened as clinically indicated.
The task force’s final recommendation statements and corresponding evidence summaries on screening children and adolescents for anxiety, depression and suicide were published online Oct. 11, 2022, in JAMA and the USPSTF website.
The final recommendations are consistent with the 2022 draft recommendation statements on these topics.
The task force emphasized that screening is only the first step in helping children and adolescents with anxiety and depression. Youth who screen positive need further evaluation to determine if they have anxiety or depression.
After diagnosis, youth should participate in shared decision-making with their parents and healthcare professional to identify the best treatment or combination of treatments.
Only a first step
In an accompanying editorial, John Walkup, MD, with Ann and Robert H. Lurie Children’s Hospital, Chicago, and coauthors made the point that, for the potential of screening for pediatric anxiety disorders to be fully realized, research focused on the process of screening from evaluation to treatment needs to be a priority.
“Perhaps most critical is developing a smart and sophisticated process of screening aligned with evidence-based treatment strategies that brings added value to routine pediatric medical care and that improves physical and mental health outcomes for children and adolescents,” they wrote.
Members of the USPSTF disclosed no relevant financial relationships. Dr. Walkup reported serving as an unpaid member of the scientific council of the Anxiety and Depression Association of America, receiving royalties for anxiety-related continuing medical education activities from Wolters Kluwer and honoraria for anxiety presentations from the American Academy of Child and Adolescent Psychiatry and the American Academy of Pediatrics.
A version of this article first appeared on Medscape.com.
For the first time, the task force recommended screening for anxiety in children aged 8-18 years who do not have a diagnosed anxiety disorder and are not showing signs or symptoms of anxiety.
This “B” recommendation reflects “moderate certainty” evidence that screening for anxiety in 8- to 18-year-olds has a moderate net benefit, the task force said.
However, the task force found “insufficient” evidence to weigh the balance of benefits and harms of screening for anxiety in children aged 7 and younger and therefore issued an “I” statement.
The task force also recommended screening for children aged 12-18 years for major depressive disorder (“B” recommendation) but said there is insufficient evidence to weigh the balance of benefits and harms of screening for depression in children aged 11 and younger (“I” statement).
These recommendations are in line with the 2016 recommendations on depression screening from the USPSTF.
“Fortunately, screening older children for anxiety and depression can identify these conditions so children and teens can receive the care that they need,” task force member Martha Kubik, PhD, RN, with George Mason University, Fairfax, Va., said in a statement.
“Unfortunately, there are key evidence gaps related to screening for anxiety and depression in younger children and screening for suicide risk in all youth,” added task force member Lori Pbert, PhD, University of Massachusetts, Worcester.
“We are calling for more research in these critical areas so we can provide health care professionals with evidence-based ways to keep their young patients healthy,” Dr. Pbert said.
Suicide screening
Turning to suicide, the task force says there is not enough evidence to recommend for or against screening for suicide risk in children and adolescents, and therefore issued an “I” statement – in line with the 2014 recommendation statement from the task force.
The task force acknowledged that the American Academy of Pediatrics, the American Foundation for Suicide Prevention, and experts from the National Institute of Mental Health have released a “Blueprint for Youth Suicide Prevention” that recommends universal screening for suicide risk in youth 12 years or older, while children aged 8-11 years should be screened as clinically indicated.
The task force’s final recommendation statements and corresponding evidence summaries on screening children and adolescents for anxiety, depression and suicide were published online Oct. 11, 2022, in JAMA and the USPSTF website.
The final recommendations are consistent with the 2022 draft recommendation statements on these topics.
The task force emphasized that screening is only the first step in helping children and adolescents with anxiety and depression. Youth who screen positive need further evaluation to determine if they have anxiety or depression.
After diagnosis, youth should participate in shared decision-making with their parents and healthcare professional to identify the best treatment or combination of treatments.
Only a first step
In an accompanying editorial, John Walkup, MD, with Ann and Robert H. Lurie Children’s Hospital, Chicago, and coauthors made the point that, for the potential of screening for pediatric anxiety disorders to be fully realized, research focused on the process of screening from evaluation to treatment needs to be a priority.
“Perhaps most critical is developing a smart and sophisticated process of screening aligned with evidence-based treatment strategies that brings added value to routine pediatric medical care and that improves physical and mental health outcomes for children and adolescents,” they wrote.
Members of the USPSTF disclosed no relevant financial relationships. Dr. Walkup reported serving as an unpaid member of the scientific council of the Anxiety and Depression Association of America, receiving royalties for anxiety-related continuing medical education activities from Wolters Kluwer and honoraria for anxiety presentations from the American Academy of Child and Adolescent Psychiatry and the American Academy of Pediatrics.
A version of this article first appeared on Medscape.com.
FROM JAMA